Nature study suggests new therapy for Gaucher disease
(Cincinnati Children's Hospital Medical Center) Scientists propose in Nature blocking a molecule that drives inflammation and organ damage in Gaucher, and maybe other lysosomal storage diseases, as a possible treatment with fewer risks and lower costs than current therapies. Reporting their data Feb. 22, the international research team conducted the study in mouse models of lysosomal storage disease and in cells from blood samples donated by people with Gaucher disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 22, 2017 Category: Cancer & Oncology Source Type: news
New Topic Page: Lipid Metabolism Disorders
Visit the new MedlinePlus Health Topic page on Lipid Metabolism Disorders.
Lipid metabolism disorders, such as Gaucher disease and Tay-Sachs disease, involve lipids. Lipids are fats or fat-like substances... (Source: What's New on MedlinePlus)
Source: What's New on MedlinePlus - August 24, 2016 Category: Consumer Health News Source Type: news
Molecule may impact Gaucher, Parkinson ’s disease
Scientists identified a molecule that restores the activity of a Gaucher disease-related enzyme and decreases alpha-synuclein protein buildup —a hallmark of Parkinson’s disease. < /p > (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - July 26, 2016 Category: Consumer Health News Source Type: news
National Gaucher Foundation Commends NIH for Continued Research on...
National Gaucher Foundation today commended National Institutes of Health scientist Dr. Ellen Sidransky for her tireless work on Gaucher disease. Her research, which was published on July 12,...(PRWeb July 18, 2016)Read the full story at http://www.prweb.com/releases/2016/07/prweb13558012.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 19, 2016 Category: Pharmaceuticals Source Type: news
Researchers advance treatment possibilities for Gaucher, Parkinson's
Bethesda, Md., Mon., July 12, 2016 - NIH researchers have identified and tested a molecule that shows promise as a possible treatment for the rare Gaucher disease and the more common Parkinson's disease. These findings demonstrate how insights from a rare disorder can have direct relevance to the treatment of more common disorders. The findings were published July 12, 2016 in The Journal of Neuroscience. (Source: NHGRI Press Releases)
Source: NHGRI Press Releases - July 12, 2016 Category: Genetics & Stem Cells Source Type: news
Researchers advance treatment possibilities for Gaucher, Parkinson's
National Institutes of Health researchers have identified and tested a molecule that shows promise as a possible treatment for the rare Gaucher disease and the more common Parkinson's disease. These findings demonstrate how insights from a rare disorder can have direct relevance to the treatment of more common disorders. Gaucher disease affects an estimated 1 in 50,000 to 1 in 100,000 people in the general population. Parkinson's disease affects more than 1 million people in North America and 7-10 million people worldwide. The findings were published July 12 in The Journal of Neuroscience. (Source: NHGRI Homepage Highlights)
Source: NHGRI Homepage Highlights - July 12, 2016 Category: Genetics & Stem Cells Source Type: news
The National Gaucher Foundation Mourns the Loss of Dr. Roscoe Brady
The National Gaucher Foundation today mourns the passing of Dr. Roscoe Owen Brady, M.D., a pioneer in medicine and the father of enzyme therapy for lysosomal diseases, including Gaucher disease.(PRWeb June 15, 2016)Read the full story at http://www.prweb.com/releases/2016/06/prweb13490867.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 15, 2016 Category: Pharmaceuticals Source Type: news
What Doctors Got Wrong About 'Good' Cholesterol
A new genetic study published in the journal Science suggests that contrary to the conventional wisdom, high levels of good cholesterol aren't necessarily heart-protective for everyone. "Twenty years ago, if you had high bad cholesterol and high good cholesterol, doctors said don’t worry about it -- one offsets the other," Dr. Scott Wright, a cardiologist at the Mayo Clinic, who wasn't involved in the study, told The Huffington Post."I never really bought that, and time has proven my skepticism to be correct. You can have a heart attack despite having a high level of good cholesterol." Doctors have long ass...
Source: Science - The Huffington Post - March 17, 2016 Category: Science Source Type: news
Lysolipid antigens prominent in MGUS and myeloma
Clonal immunoglobulin reactive to lyso-glucosylceramide (LGL1), which is elevated in Gaucher disease, was found in patients with Gaucher disease as well as in one third of patients with sporadic... (Source: Family Practice News)
Source: Family Practice News - February 10, 2016 Category: Primary Care Source Type: news
Gaucher disease may protect against Parkinson's disease-related color visual impairment
Parkinson's Disease (PD) patients have a five-fold greater risk of carrying genetic mutations in the β-glucocerebrosidase gene (GBA), which are commonly associated with Gaucher disease (GD). (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - November 11, 2015 Category: Neurology Tags: Parkinson's Disease Source Type: news
Gaucher disease may protect against Parkinson's disease-related color visual impairment
Parkinson’s Disease (PD) patients have a five-fold greater risk of carrying genetic mutations in the ?-glucocerebrosidase gene (GBA), which are commonly associated with Gaucher disease (GD). Patients with both PD and GD tend to experience earlier onset of PD and more serious cognitive changes than PD patients without the mutations. A new study suggests that GD or the presence of GBA mutations may actually shield patients from deficiency in visual color discrimination, which is a hallmark of PD. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 10, 2015 Category: Science Source Type: news
Gaucher disease may protect against Parkinson's disease-related color visual impairment
(IOS Press) Patients with both PD and GD tend to experience earlier onset of PD and more serious cognitive changes than PD patients without the mutations. A new study published in the Journal of Parkinson's Disease suggests that GD or the presence of GBA mutations may actually shield patients from deficiency in visual color discrimination, which is a hallmark of PD. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 10, 2015 Category: Global & Universal Source Type: news
Sanofi says Cerdelga trial shows promise
PARIS (Reuters) - French pharmaceutical group Sanofi said on Tuesday a trial treatment with its Cerdelga drug for patients with type 1 Gaucher disease, a rare genetic disorder, showed promise. (Source: Reuters: Health)
Source: Reuters: Health - February 17, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Eliglustat (Cerdelga) Approved in Europe for Gaucher DiseaseEliglustat (Cerdelga) Approved in Europe for Gaucher Disease
The oral glucosylceramide analog is indicated for long-term treatment of adults with type 1 Gaucher disease. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 23, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Genzyme’s Cerdelga receives European approval to treat Gaucher disease type 1
Sanofi subsidiary Genzyme has received marketing approval from European Commission (EC) for its Cerdelga (eliglustat) capsules to treat adult patients with Gaucher disease type 1. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 23, 2015 Category: Pharmaceuticals Source Type: news
